Meridian Bioscience (VIVO) Tops Q2 EPS by 8c, Offers Guidance
Get Alerts VIVO Hot Sheet
Price: $33.97 --0%
Revenue Growth %: -100.0%
Financial Fact:
BASIC EARNINGS PER COMMON SHARE: 0.13
Today's EPS Names:
SHIM, KOD, HEWA, More
Revenue Growth %: -100.0%
Financial Fact:
BASIC EARNINGS PER COMMON SHARE: 0.13
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.56, $0.08 better than the analyst estimate of $0.48. Revenue for the quarter came in at $85.3 million versus the consensus estimate of $84.5 million.
GUIDANCE:
Meridian Bioscience sees FY2021 EPS of $1.60-$1.80, versus the consensus of $1.66. Meridian Bioscience sees FY2021 revenue of $305-335 million, versus the consensus of $324 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Walgreens Boots Alliance (WBA) tops Q2 expectations, narrows full-year profit forecast
- Stran & Company, Inc. (SWAG) Misses Q4 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!